Interim Report for January-September 2017 will be published on Thursday, 26 October 2017 approximately at 12.00 noon Finnish time (EEST).
|8/1/2017||146,000 Orion Corporation A shares converted into B shares|
|7/19/2017||Orion Group Half-Year Financial Report January-June 2017|
|7/19/2017||Orion Corporation's financial reporting and Annual General Meeting in 2018|
|6/19/2017||187,133 Orion Corporation A shares converted into B shares|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.